The most important financial indicators for the company Est Invest Farma Srl - Unique Identification Number 29554284:
sales in 2023 was
196.120
euro, registering a net profit of
3.215
euro and having an average number of
5
employees.
Firma isi desfasoara activitatea in domeniul Comert cu ridicata al produselor farmaceutice having the NACE code 4646.
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded.
In the last year of activity, the sales decreased by -3.2%, from 203.262 euro in the year 2022, to 196.120 euro in 2023.
The Net Profit decreased by -4.892 euro, from 8.131 euro in 2022, to 3.215 in the last year.
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
Debts, Equity, Inventories, Receivables, Accounts, Assets -
Est Invest Farma Srl - CUI 29554284
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Fixed Assets
123
81
24.078
19.221
32.208
24.405
16.035
7.947
5.022
1.580
Current Assets
64.417
74.583
103.419
144.901
171.951
201.301
238.884
222.188
211.007
203.380
Inventories
6.458
10.999
7.116
28.104
27.695
42.517
65.067
49.839
50.126
72.913
Receivables
57.503
62.925
90.063
124.584
131.538
165.957
148.799
123.172
137.546
129.598
Cash
456
659
6.241
-7.787
12.718
-7.173
25.018
49.177
23.334
869
Shareholders Funds
23.523
33.814
78.535
112.706
136.103
160.316
168.732
163.143
148.316
133.280
Social Capital
45
45
45
44
43
42
41
40
41
40
Debts
41.017
40.851
51.355
52.252
68.057
65.390
86.187
66.992
67.713
71.680
Income in Advance
0
0
0
0
0
0
0
0
0
0
Exchange rate - RON
4.9465
4.9315
4.9468
4.8371
4.7454
4.6535
4.5681
4.4908
4.445
4.4821
Main CAEN
"4646 - 4646"
CAEN Financial Year
4646
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
203.380 euro in 2023 which includes Inventories of
72.913 euro, Receivables of
129.598 euro and cash availability of
869 euro.
The company's Equity was valued at
133.280 euro, while total Liabilities amounted to
71.680 euro.
Equity decreased by -14.586 euro, from 148.316 euro in 2022, to 133.280 in 2023.
Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Est Invest Farma Srl